Entecavir: A step forward in combating hepatitis B disease

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 17, 2008, Pages 3095-3109

  Yurdaydin, Cihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Entecavir; Metabolism; Pharmacodynamics; Safety and efficacy

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LOBUCAVIR; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; HEPATITIS B; HEPATITIS VIRUS; HUMAN; IC 50; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B; HUMANS;

EID: 57549106207     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802515546     Document Type: Review

References (82)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
3. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29
4. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46
5. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S303-9
6. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46
7. Banatvala J, Van Damme P, Emiroglu N. Hepatitis B immunisation in Britain: time to change? BMJ 2006;332:804-5
8. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescants in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800
9. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Study Group. N Engl J Med 1997;336:1855-9
10. de Franchis R, Meucci G, Vecchi M, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-4
11. Manno M, Camma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004;127:756-63
12. Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;132:1586-94
13. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75
14. Iloeje UH, Yang HI, Su J, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:676-86
15. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;97:265-72
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
17. Liaw YF, Sung JJY, Chow DHF, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
19. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. NEJM 2005;352:2682-95
20. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEJM 2004;351:1206-17
21. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679-93
22. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B: week 72 data and week 24 adefovir dipivoxil switch data [abstract]. J Hepatol 2008;48(Suppl 2):S32
23. Tyzeka (package insert). Novartis Pharma Stein AG, Stein, Switzerland, November 2007. Available from: www.pharma.us.novartis.com/product/pi/pdf/ tyzeka.pdf
24. EMEA public statement, London, 14 February 2008 EMEA/60439/2008
25. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B patients [abstract]. Hepatology 2006;44(Suppl 1:)548A
26. Szczech LA. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context. J Infect Dis 2008;197:7-9
27. Slusarchyk WA, Field AK, Greytok JA, et al. 4-Hydroxy-3-(hydoxymethyl)-2-methylenecyclopentyl purines and pyrimidines, a new class of anti-herpesvirus agents. Antiviral Res 1992;17(Suppl 1):98
28. Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8
29. Bisachhi GS, Chao ST, Bachard C, et al. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti hepatitis B virus activity in vitro Bioorg Med Chem Lett 1997;7:127-32
30. Seeger C, Summers J, Mason WS. Viral DNA synthesis. Curr Top Microbiol Immunol 1991;168:41-59
31. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerase by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8
32. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-8
33. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3
34. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007;81:3992-4001
35. Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209-17
36. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45
37. Wolters LMM, Hansen B, Niesters HGM, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-44
38. Leung N, Sherman M, Peng CY, et al. Entecavir results in higher HBV DNA reductions vs. adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 48 weeks results [abstract]. Gastroenterology 2007;132:A764
39. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006;46:1250-8
40. Baraclude (package insert). Princeton, NJ: Bristol Myers Squibb, 2008
41. Bifano M, Yan JH, Xie J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir [abstract]. Hepatology 2004;40(Suppl 1):663A
42. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
43. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
44. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis virus replication and drug resistance. J Clin Invest 2001;107:449-55
45. Levine S, Hernandez G, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro Antimicrob Agents Chemother 2002;46:2525-32
46. Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902
47. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus transcriptase substitutions associated with entecavir resistance. Hepatology 2008;47:1473-82
48. Chang TT, Gish RG, Hadziyannis SJ, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
49. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
50. Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2008;2:A88-89
51. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with chronic hepatitis B. Hepatology 2006;44:1656-65
52. Delaney WE 4th, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro J Virol 2003;77:11833-41
53. Melegari M, Bruno S, Wands JR. Properties of hepatitis B virus pre-S1 deletion mutants. Virology 1994;199:292-300
54. Walsh A, Langley D, Rose R, et al. Mechanistic characterization of entecavir resistance in lamivudine resistant hepatitis B virus. Antiviral Res 2006;70:A36
55. Lattora D, Campbell K, Wolter A, Hurley JM. Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid primers. Hum Mutat 2003;22:79-85
56. De Man RA, Wolters LMM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82
57. Yao GB, Zhang DF, Wang BE, et al. A study of the dosage and efficacy of entecavir for treating hepatitis B virus. Zhonghua Gan Zang Bing Za Zhi 2005;13:484-7
58. Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8
59. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209
60. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
61. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007;1:365-72
62. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
63. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HbeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
64. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991;1:431-5
65. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HbeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
66. Han S, Chang TT, Chao YC, et al. Four-year entecavir treatment in nucleoside-naïve HBeAg-positive patients: results from studies ETV-022 and -901 [abstract]. Hepatology 2007;46:654A
67. Takehara T, Hayashi N, Takaguchi K, et al. Efficacy and safety of 3 years treatment with entecavir in Japanese nucleoside-naïve patients with chronic hepatitis B [abstract]. Hepatol Int 2008;2:A97-98
68. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical and serology outcomes through 96 weeks. Hepatology 2008;48:99-108
69. Tenney DJ, Baldick CJ, Rose RE, et al. Only a subset of HBV substitutions at entecavir resistance residues lead to phenotypic resistance and virologic rebound [abstract]. Hepatology 2006;44:253A
70. Yurdaydin C, Idilman R, Çevik E, et al. Adefovir treatment of entecavir resistance in patients with lamivudine-refractory chronic hepatitis B [abstract]. J Hepatol 2008;48(Suppl 2):S255
71. Mazzucco CE, Hamatake RK, Colonno R, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008;52:598-605
72. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir- effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21
73. Jakobsen MR, Arildsen H, Krarup HB, et al. Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naïve patient. Clin Infect Dis 2008;46:e88-91
74. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
75. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
76. Janssen HL, van Zonnenfeld M, Senturk H, et al. Pegylated interferon alfa 2b alone or in combination with lamivudine for HbeAg-positive chronic hepatitis B patients B: a randomized trial. Lancet 2005;365:123-9
77. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32
78. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
79. Fried MW, Piratvisuth T, Lau GKK, et al. HbeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HbeAg-positive chronic hepatitis B. Hepatology 2008;47:428-34
80. Brunetto M, Moriconi F, Cavallone D, et al. Reduction in serum HBsAg level in patients with chronic hepatitis B infected with genotype D induced pegylated interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study [abstract]. Hepatology 2007;46(Suppl 1):679A
81. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12
82. Buti M, Elefsiniotis I, Jardi R, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007;47:366-72